F2G
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
F2G
Industry:
Biotechnology Genetics Health Care Medical Pharmaceutical
Founded:
1998-01-01
Address:
Manchester, Manchester, United Kingdom
Country:
United Kingdom
Website Url:
http://www.f2g.com
Total Employee:
251+
Status:
Active
Contact:
44 (0)161 785 1270
Email Addresses:
[email protected]
Total Funding:
283.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apache Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Aprea
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
Aptahem
Aptahem develops aptamer-based drugs for the treatment of acute life-threatening conditions
Aptarion biotech
Aptarion biotech is a developer Biostable L-Aptamers for the treatment Of Life-Threatening diseases And for Biosensors.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Forendo Pharma
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
GenSight Biologics
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
ISCA Diagnostics
ISCA Diagnostics is specialising in point-of-care tests for life-threatening fungal infections of humans.
LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Methuselah Health
Methuselah Health identifies novel targets for treatment of ageing-related diseases.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
RespiVert
Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases.
Travere Therapeutics
Travere discovers and develops drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening.
SkinJect
SkinJect develops a novel drug delivery system for the treatment of non-melanoma skin cancers.
Smart Cells
Smart Cells provides stored stem cell units for use in the treatment of children with life-threatening illnesses.
TopoTarget UK Limited
TopoTarget UK Limited is discovers and develops drugs for the treatment of proliferative diseases.
Vical
Vical develops biopharmaceutical drugs to prevent and treat chronic or life-threatening infectious diseases.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Private Equity Round - F2G
Sofinnova Partners
Sofinnova Partners investment in Private Equity Round - F2G
Brace Pharma
Brace Pharma investment in Private Equity Round - F2G
Morningside Venture Investments
Morningside Venture Investments investment in Private Equity Round - F2G
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Private Equity Round - F2G
Novo Ventures
Novo Ventures investment in Private Equity Round - F2G
Advent Life Sciences
Advent Life Sciences investment in Private Equity Round - F2G
European Investment Bank
European Investment Bank investment in Debt Financing - F2G
Sectoral Asset Management
Sectoral Asset Management investment in Private Equity Round - F2G
Aisling Capital
Aisling Capital investment in Private Equity Round - F2G
Official Site Inspections
http://www.f2g.com Semrush global rank: 9.53 M Semrush visits lastest month: 141
- Host name: f2gcorp.tempurl.host
- IP address: 136.244.82.232
- Location: Frankfurt am Main Germany
- Latitude: 50.1103
- Longitude: 8.7147
- Timezone: Europe/Berlin
- Postal: 60314
More informations about "F2G" on Search Engine
Novel Therapeutics for Rare Fungal Infections | F2G
WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. F2G is transforming the fight against rare, invasive fungal infections by developing novel …See details»
A Scientific Breakthrough in Antifungal Treatments | F2G
A Scientific Breakthrough in Antifungal Treatments | F2G. Science. Uncovering a novel compound. Combining our expertise in fungal molecular biology and biochemistry, we identify and develop novel antifungal compounds.See details»
F2G - Crunchbase Company Profile & Funding
Organization. F2G. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. About. F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases. Manchester, Manchester, United Kingdom. 11-50. Private Equity. www.f2g.com. 13,109. Highlights. Total Funding Amount. Unlock for free.See details»
Fighting the rising tide of antifungal resistance: a global …
F2G raises $61M for late-phase antifungal R&D | Fierce Biotech
Aug 12, 2020 With a phase 2b data drop in sight, F2G has raised the additional capital to fund late-phase work and scale up its organization in anticipation of the approval and commercialization of...See details»
Shionogi, F2G team up on rare fungal disease drug - Fierce Biotech
May 16, 2022 F2G envisages physicians using olorofim in serious invasive fungal diseases. ( (Getty/Natee Meepian)) Shionogi is betting $100 million upfront on a new class of antifungal medicine, teaming up...See details»
F2G Announces FDA Filing Acceptance of New Drug Application …
PRINCETON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- F2G Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for olorofim...See details»
F2G and Shionogi Present Full Data Set from Pivotal …
Oct 21, 2023 F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections. F2G has commercial...See details»
F2G - The Pharma Letter
F2G is a UK- and Austria-based biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. "F2G has discovered and developed a completely new class …See details»
We’re Driving Innovation in Antifungal Therapeutics | We Are F2G
We believe that the world’s greatest health challenges can be solved when radical hope is grounded in cutting-edge science. At F2G (Functional Fungal Genomics), we focus on developing first-in-class medicines to treat rare, life-threatening fungal infections.See details»
F2G — Sofinnova Partners
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. F2G is based in the U.K., the U.S. and Austria.See details»
We’re Fighting the Fungal Infection Crisis | F2G
In 2022, the World Health Organization (WHO) released a Fungal Priority Pathogens List (FPPL) based on antifungal resistance, deaths, annual incidence, and other clinical factors. 1 Our team aims to target some of the fungi on the FPPL, including Aspergillus fumigatus, Coccidioides species, and rare molds.See details»
F2G - Funding, Financials, Valuation & Investors - Crunchbase
F2G has raised a total of. $283.3M. in funding over 12 rounds. Their latest funding was raised on Aug 4, 2022 from a Private Equity round. F2G is funded by 20 investors. Forbion Capital Partners and Sofinnova Partners are the most recent investors. Unlock for free.See details»
F2G - Contacts, Employees, Board Members, Advisors & Alumni
Organization. F2G. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 8. Number of Board Member and Advisor Profiles 9. Contacts 30. About. F2G has 8 current employee profiles, including Chief Executive Officer Ian Nicholson.See details»
Goodyear F2G Corsair - Wikipedia
The Goodyear F2G Corsair, often referred to as the " Super Corsair ", is a development by the Goodyear Aircraft Company of the Vought F4U Corsair fighter aircraft. The F2G was intended as a low-altitude interceptor and was equipped with a 28-cylinder, four-row Pratt & Whitney R-4360 air-cooled radial engine.See details»
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b …
Oct 21, 2023 MANCHESTER, United Kingdom and OSAKA, Japan, Oct. 21, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. and Shionogi & Co., Ltd., today announced full results from the pivotal Phase 2b open-label study (Study...See details»
F2G Organization | IEEE Conference Publication | IEEE Xplore
F2G Organization Abstract: Provides general conference information and includes a listing of current committee members and society officers. Published in: 2010 3rd International Conference on Human-Centric ComputingSee details»
Ian Nicholson - Chief Executive Officer @ F2G - Crunchbase
Overview. Number of Current Board & Advisor Roles 1. CB Rank (Investor) 175,141. Primary Job Title Chief Executive Officer. Primary Organization. F2G. Location Oxford, Oxfordshire, United Kingdom. Regions Europe, Middle East, and Africa (EMEA) Gender Male. LinkedIn View on LinkedIn.See details»
Contact Us and Discover the Future of Antifungal Treatments | F2G
ARRIVE Blue. Blue Tower. Media City, M50 2ST. United Kingdom. Email. [email protected]. Phone. +44 (0)161 785 1270. USA Headquarters. F2G Inc. 506 Carnegie Center Drive.See details»
F2G - Wikipedia
F2G. F2G may refer to: Eberhart F2G, a circa 1920's aircraft. Goodyear F2G Corsair, a circa 1940's aircraft. Category: Letter–number combination disambiguation pages.See details»